Keystone Symposia Conference | Imaging and Drug Development

Meeting Program

To view program in "24 hour" time (international) click here.

Sunday, February 22
3:00 - 7:30 PM	Registration	Kokopelli's
6:30 - 7:30 PM	Refreshments	Kokopelli's
7:30 - 8:30 PM	Keynote Address Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn B
	Steven M. Larson, Memorial Sloan-Kettering Cancer Center, USA Molecular Imaging in Drug Discovery for Oncology

Monday, February 23
7:00 - 8:00 AM	Breakfast	Kokopelli's
8:00 - 11:00 AM	Advances in Radiochemistry Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn B
	Christer Halldin, Karolinska Institutet, Sweden Advances in Radiotracer Design and Radiosynthesis of PET Ligands - What are the Remaining Hurdles for Small Molecular Drugs?
	Michael R. Zalutsky, Duke University, USA Advances in Radiotracer Design and Radiosynthesis of Large Biologicals as PET Ligands - Impact and Future Opportunity
	Joanna Fowler, Brookhaven National Laboratory, USA Radiotracer Development and Application in Neuroscience
	Victor Pike, National Institutes of Health, USA PET Radiotracers: Facing the Biological Reality - BBB and Metabolic Enzymes
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Kokopelli's
11:00 AM- 1:00 PM	Poster Setup	Big Horn C
11:00 AM-	On Own for Lunch
1:00 - 10:00 PM	Poster Viewing	Big Horn C
2:30 - 4:30 PM	Workshop 1: Sharing of PET Radiotracers	Big Horn B
	Short Talks to be Chosen from Abstracts, , USA
4:30 - 5:00 PM	Coffee Available	Kokopelli's
5:00 - 7:00 PM	Advances in Instrumentation Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn B
	David W. Townsend, University of Tennessee Medical Center, USA Development and Impact of PET/CT - Limits and Future Direction
	Julie L. Sutcliffe, University of California, Davis, USA Highthroughput in vivo Screening of Targeted Molecular Imaging Agents
	Charles Peck, IBM T.J. Watson Research Center, USA Performance Gaps beyond the Imaging Instruments: Advances in Data Acquisition and Analysis
	Short Talk to be Chosen from Abstracts,
7:30 - 10:00 PM	Poster Session 1 Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn C
8:00 - 9:00 PM	Social Hour w/ Lite Bites	Kokopelli's
Tuesday, February 24
7:00 - 8:00 AM	Breakfast	Kokopelli's
8:00 - 11:00 AM	Molecular Imaging: From Basic to Clinical Research Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn B
	Lars Farde, AstraZeneca R&D Södertälje, Sweden Molecular Imaging in Neuroscience: From Bench to Bedside
	Marc Laruelle, GlaxoSmithKline, UK Application of PET in Translational Medicine: From Proof of Mechanism to Clinical Dose Selection
	Eric O. Aboagye, Imperial College, UK Evaluation of PET Radiotracers in Translational Models for Oncology - Limitations and Developments in Animal Models Relevant to Cancer Imaging

	Ronald Blasberg, Memorial Sloan-Kettering Cancer Center, USA Reporter Gene Imaging Studies in Patients: Issues to Address
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Kokopelli's
11:00 AM- 1:00 PM	Poster Setup	Big Horn C
11:00 AM-	On Own for Lunch
1:00 - 10:00 PM	Poster Viewing	Big Horn C
2:30 - 4:30 PM	Workshop 2: Challenges of Multi-Center Trials Using Molecular Imaging	Big Horn B
	Short Talks to be Chosen from Abstracts, , USA
4:30 - 5:00 PM	Coffee Available	Kokopelli's
5:00 - 7:00 PM	Molecular Imaging of Biological Effects Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn B
	Paul Grasby, MRC Clinical Sciences Centre, UK Application of PET in Translational Medicine: From Measuring Blood Flow to Transmitter Release

	Speaker to be Announced,

	Tetsuya Suhara, National Institute of Radiological Sciences, Japan Imaging Biomarker for Proof of Concept
	Short Talk to be Chosen from Abstracts,
7:30 - 10:00 PM	Poster Session 2 Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn C
8:00 - 9:00 PM	Social Hour w/ Lite Bites	Kokopelli's
Wednesday, February 25
7:00 - 8:00 AM	Breakfast	Kokopelli's
8:00 - 11:00 AM	Proof of Biological Activity and Mechanism of Action Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn B
	Anthony Shields, Wayne State University, USA The Use of PET to Image Proliferation in Early Oncology Trials - Status and Use in Drug Development & Patient Management
	Timothy J. McCarthy, Pfizer, USA The Use of FDG-PET to Image Glucose Utilization: The Experience from Sunitinb - Does this Support Wide Utilization of FDG-PET in Early Drug Development
	Eric Reiman, Banner Alzheimer's Institute, USA Positron Emission Tomography in the Evaluation of Alzheimer’s Disease-Slowing and Prevention Therapies
	Julie C. Price, University of Pittsburgh, USA PET Amyloid Imaging
	Short Talk(s) to be Chosen from Abstracts,
9:20 - 9:40 AM	Coffee Break	Kokopelli's
11:00 AM-	On Own for Lunch
2:30 - 4:30 PM	Workshop 3: Challenges for Biomarker Qualification/Validation	Big Horn B
	Short Talks to be Chosen from Abstracts, , USA
4:30 - 5:00 PM	Coffee Available	Kokopelli's
4:30 - 7:00 PM	Proof of Concept (Biomarker to Surrogate) Registered attendees for this meeting can view Abstracts for this session starting on 01/22/2009	Big Horn B
	Gary J. Kelloff, National Institutes of Health, USA Biomarker Qualification and Validation as a Surrogate in Lymphoma and Lung Cancer - Current Progress and Future Challenges for Use in Drug Development
	Dean F. Wong, Johns Hopkins Medicine, USA Neuroreceptor Imaging: Proof of Concept Prebiomarker or Potential Surrogate Marker?
	Wayne Drevets, Mood and Anxiety Disorders Program, NIMH, USA Using Molecular Imaging to Identify Phenotypic Differences between Mood Disorder Subtypes
	Short Talk to be Chosen from Abstracts,
7:00 - 8:00 PM	Social Hour w/ Lite Bites	Kokopelli's
8:00 - 9:00 PM	Entertainment	Big Horn C
Thursday, February 26
	Departure
*=Session Chair †=Speaker invited, not yet responded.

We gratefully acknowledge support for this conference from:

IBM Corporation

We gratefully acknowledge the companies that provide Keystone Symposia with additional meeting support, including marketing and advertising...

Click here to view these companies

Positron Emission Tomography (PET) is maturing into a key scientific tool, which is increasingly applied in the scientific community and pharmaceutical industry to study drug distribution, drug-target interactions, and disease processes, especially in CNS and oncology areas. Using specific radiotracers, PET can be performed serially over time in the same live subject to study receptor occupancy and pharmacodynamic response of drug action. These studies can facilitate the selection of drug candidates to advance to clinical trials and guide clinical dose selection. This non-invasive technology also allows longitudinal studies to elucidate the underlying pathophysiology of disease, follow the progression, and monitor the outcome of treatment. The combination of genomic knowledge with PET imaging will provide more specific phenotypes that can help to identify genetic predictors of drug response. The objective of this conference is to bring together a wide range of academic and industrial scientists within the PET molecular imaging community with expertise in imaging systems, analytical tools, and drug discovery/development to address some key issues common to the fields of neurology and oncology. The meeting will provide a forum for the cross-fertilization of experience across these two disciplines, including sharing of knowledge in the development and usage of radiotracers, identifying gaps and opportunities in using PET to facilitate drug development, and discussing innovative solutions to overcome challenges in multi-center trials and biomarker qualification/validation.

Imaging and Drug Development (C1)